Systematic Review of Gossypol/at-101 in Cancer Clinical Trials

Institutional Review Board Statement:
Not applicable.
Informed Consent Statement:
Not applicable.
Data Availability Statement:
No new data were created or analyzed in this study. Data sharing is
not applicable to this article.
Acknowledgments:
We would like to thank Monika Schumacher for editorial assistance.
Conflicts of Interest:
The authors declare that they have no conflict of interest.
Abbreviations
ADT
androgen deprivation therapy
AE
adverse events
AIF
apoptosis-inducing factor
ALT
alanine aminotransferase
APE1/Ref-1
apurinic/apyrimidinic endonuclease 1/redox enhancing factor-1
AST
aspartate aminotransferase
AUC
area under the concentration time curve
BID
latin: bis in die; twice a day
Bcl-2
B-cell lymphoma 2
BH3
Bcl-2 homology domain 3
CEA
carcinoembryonic antigen
CHD1
chromodomain helicase DNA-binding protein
co
control
cCR
clinical complete response
CR
complete response
CRPC
castrate-resistant prostate cancer
CTCAE
Common Terminology Criteria for Adverse Events
CXCL8
chemokine C-X-C motif ligand 8
DCR
disease control rate
DLT
dose-limiting toxicity
DNA
deoxyribonucleic acid
ECG
electrocardiogram
ECOG
Eastern Cooperative Oncology Group
eg
experimental group
EGFR
epidermal growth factor receptor
ES-SCLC
extensive stage—small cell lung cancer
GEC
gastroesophageal carcinoma
GI
gastrointestinal
HDAC
histone deacetylase
HDACi
histone deacetylase inhibitor
HNSCC
head and neck squamous cell carcinoma
IL-8
interleukin-8
IV
intravenously
LHRH
luteinizing hormone-releasing hormone
MOMP
mitochondrial outer membrane permeabilization
mOS
median overall survival
mPFS
median progression-free survival
MR
minor response
MTD
maximally tolerated dose
n. a.
not available
ORR
objective response rate
OR
objective response
OS
overall survival

---

Pharmaceuticals
2022
,
15
, 144
28 of 33
P-gp
p-glycoprotein
PBMC
peripheral blood mononuclear cell
PCWG
Prostate Cancer Clinical Trials Working Group
PD
progressive disease
PFS
progression-free survival
PO BID
latin: per os bis in die; orally, twice a day
PO QD
latin: per os quaque die; orally, once a day
PR